# Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

> **NCT05727176** · PHASE2 · RECRUITING · sponsor: **Taiho Oncology, Inc.** · enrollment: 120 (estimated)

## Conditions studied

- Advanced Cholangiocarcinoma
- FGFR2 Fusions
- Gene Rearrangement

## Interventions

- **DRUG:** TAS-120

## Key facts

- **NCT ID:** NCT05727176
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-05
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05727176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05727176, "Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05727176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*